CompletedPHASE1, PHASE2NCT01301430

Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Oryx GmbH & Co. KG
Principal Investigator
Andreas Unterberg, Prof. Dr.
Department of Neurosurgery, University Hospital Heidelberg
Intervention
H-1PV(drug)
Enrollment
18 enrolled
Eligibility
18 years · All sexes
Timeline
20112015

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01301430 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials